PMID- 23508822
OWN - NLM
STAT- MEDLINE
DCOM- 20131211
LR  - 20240229
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
VI  - 24
IP  - 7
DP  - 2013 Jul
TI  - Sorafenib combined with transarterial chemoembolization for the treatment of 
      advanced hepatocellular carcinoma: a large-scale multicenter study of 222 
      patients.
PG  - 1786-1792
LID - S0923-7534(19)36649-9 [pii]
LID - 10.1093/annonc/mdt072 [doi]
AB  - BACKGROUND: Data on the efficacy and safety of sorafenib in combination with 
      transarterial chemoembolization (TACE) in patients with advanced hepatocellular 
      carcinoma (HCC) are lacking. PATIENTS AND METHODS: In this multicenter 
      retrospective study, 222 consecutive HCC patients receiving combination therapy 
      were enrolled between June 2008 and July 2011. RESULTS: Chronic hepatitis B was 
      the predominant cause of HCC (86%). Eighty percent patients were at Barcelona 
      Clinic Liver Cancer (BCLC) stage C, and 86% patients were in Child-Pugh (CP) A 
      class. The overall median survival was 12 months (95% CI 10.1-13.9). The overall 
      incidence of adverse events (AEs) was 87%. In 177 BCLC-C patients, performance 
      status, the number of HCC nodules, Child-Pugh score and macrovascular invasion 
      were significantly associated with overall survival (OS) and were included in the 
      final risk scores (R), where R = 5 x (vascular invasion: 0 if no, 1 yes) + 6 x 
      (CP: 0 if A, 1 if B) + 7 x (no. of lesions: 0 if 1-2, 1 >/=3) + 8 x ( Eastern 
      Cooperative Oncology Group, ECOG: 0 if 0, 1 >/=1). CONCLUSIONS: Sorafenib in 
      combination with TACE should be considered a safe and effective therapy for 
      advanced HCC. Further validation of the new subgroup of BCLC-C stage is warranted 
      in an independent patient cohort.
FAU - Zhao, Y
AU  - Zhao Y
AD  - Department of Liver Disease and Digestive Interventional Radiology, Xijing 
      Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an.
FAU - Wang, W J
AU  - Wang WJ
AD  - Department of Liver Disease and Digestive Interventional Radiology, Xijing 
      Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an.
FAU - Guan, S
AU  - Guan S
AD  - Department of Interventional Radiology, the First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou.
FAU - Li, H L
AU  - Li HL
AD  - Department of Radiology, Henan Tumor Hospital, Zhengzhou.
FAU - Xu, R C
AU  - Xu RC
AD  - Department of Hepatobiliary and Pancreatic Medicine, Hunan Provincial Tumor 
      Hospital, Changsha.
FAU - Wu, J B
AU  - Wu JB
AD  - Department of Oncology, the Second Affiliated Hospital of Nanchang University, 
      Nanchang.
FAU - Liu, J S
AU  - Liu JS
AD  - Department of Minimally Invasive Medicine, Hunan Province People's Hospital, 
      Changsha.
FAU - Li, H P
AU  - Li HP
AD  - Department of Interventional Radiology, Xiangya Hospital of Central-south 
      University, Changsha.
FAU - Bai, W
AU  - Bai W
AD  - Department of Liver Disease and Digestive Interventional Radiology, Xijing 
      Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an.
FAU - Yin, Z X
AU  - Yin ZX
AD  - Department of Liver Disease and Digestive Interventional Radiology, Xijing 
      Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an.
FAU - Fan, D M
AU  - Fan DM
AD  - Department of Liver Disease and Digestive Interventional Radiology, Xijing 
      Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an; State 
      Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, 
      Fourth Military Medical University, Xi'an, China.
FAU - Zhang, Z L
AU  - Zhang ZL
AD  - Department of Liver Disease and Digestive Interventional Radiology, Xijing 
      Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an; 
      Department of Radiology, Northwestern University, Chicago, USA.
FAU - Han, G H
AU  - Han GH
AD  - Department of Liver Disease and Digestive Interventional Radiology, Xijing 
      Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an. 
      Electronic address: guohhan@126.com.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20130318
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*administration & dosage/adverse effects
MH  - Carcinoma, Hepatocellular/mortality/pathology/*therapy
MH  - *Chemoembolization, Therapeutic
MH  - Combined Modality Therapy
MH  - Diarrhea/chemically induced
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Liver Neoplasms/mortality/pathology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Niacinamide/administration & dosage/adverse effects/*analogs & derivatives
MH  - Phenylurea Compounds/*administration & dosage/adverse effects
MH  - Proportional Hazards Models
MH  - ROC Curve
MH  - Retrospective Studies
MH  - Sorafenib
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - hepatocellular carcinoma
OT  - sorafenib
OT  - transarterial chemoembolization
EDAT- 2013/03/20 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/03/20 06:00
PHST- 2013/03/20 06:00 [entrez]
PHST- 2013/03/20 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - S0923-7534(19)36649-9 [pii]
AID - 10.1093/annonc/mdt072 [doi]
PST - ppublish
SO  - Ann Oncol. 2013 Jul;24(7):1786-1792. doi: 10.1093/annonc/mdt072. Epub 2013 Mar 
      18.